{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 31,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 45,
  "notes": "The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/8",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "In vivo efficacy tumor regression bar chart",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c6da9bb-2bb8-4812-bfb2-c39a68c4d081",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Resistance Mutations IC50 dot plot",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "599e9d4c-c166-4dd9-9ad2-5f4294199d50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.08,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Fusion Partners IC50 dot plot",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ff159a9-7595-4692-bfb1-f55e6e92b2e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.07,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "BID, twice daily; IC50, half-maximal inhibitory concentration; PDC, patient-derived cell line. Sources: Tangpeerachaikul, A. et al., AACR 2022; Deshpande, A. et al., EORTC-NCI-AACR 2021; Pelish, H.E. et al., AACR 2021.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6612cab6-4191-4782-8a5d-40e5b7112d30",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preclinical | NVL-520 Exhibits Potent Activity Across Diverse ROS1 Fusion Partners and Resistance Mutations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "797f7e94-f2a1-4a21-95b1-2e84f1ff6182",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b01545f0-fd92-41f4-970e-28b5cb49def6",
      "evidence": "Slides 6-16 discuss the limitations of current treatments and the potential benefits of Nuvalent's therapies.",
      "position": 0,
      "objective": "What is the cost of not developing effective treatments for cancer patients with specific genetic mutations?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}